seed
Stage
2
Investors
About
Medsenic is a clinical-stage biotechnology company developing a new generation of arsenic-based drugs for autoimmune diseases and oncology. Its lead product, Arscimed®, is currently in clinical trials for severe autoimmune diseases.
Explore Medsenic's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.